1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Peritoneal Tumor - Pipeline Review, H1 2014

Peritoneal Tumor - Pipeline Review, H1 2014

  • March 2014
  • -
  • Global Markets Direct
  • -
  • 69 pages

Peritoneal Tumor - Pipeline Review, H1 2014

Summary

Global Markets Direct’s, ‘Peritoneal Tumor - Pipeline Review, H1 2014’, provides an overview of the Peritoneal Tumor’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Peritoneal Tumor, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peritoneal Tumor and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Peritoneal Tumor
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Peritoneal Tumor and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Peritoneal Tumor products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Peritoneal Tumor pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Peritoneal Tumor
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Peritoneal Tumor pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Peritoneal Tumor - Pipeline Review, H1 2014
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Peritoneal Tumor Overview 6
Therapeutics Development 7
Pipeline Products for Peritoneal Tumor - Overview 7
Pipeline Products for Peritoneal Tumor - Comparative Analysis 8
Peritoneal Tumor - Therapeutics under Development by Companies 9
Peritoneal Tumor - Therapeutics under Investigation by Universities/Institutes 11
Peritoneal Tumor - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Peritoneal Tumor - Products under Development by Companies 14
Peritoneal Tumor - Products under Investigation by Universities/Institutes 15
Peritoneal Tumor - Companies Involved in Therapeutics Development 16
Boehringer Ingelheim GmbH 16
Amgen Inc. 17
Eli Lilly and Company 18
Cell Therapeutics, Inc. 19
MEI Pharma, Inc. 20
Recepta Biopharma S.A. 21
AbbVie Inc. 22
Peritoneal Tumor - Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Target 24
Assessment by Mechanism of Action 27
Assessment by Route of Administration 30
Assessment by Molecule Type 32
Drug Profiles 34
trebananib - Drug Profile 34
Product Description 34
Mechanism of Action 34
RandD Progress 34
paclitaxel poliglumex - Drug Profile 38
Product Description 38
Mechanism of Action 38
RandD Progress 38
idronoxil - Drug Profile 42
Product Description 42
Mechanism of Action 42
RandD Progress 42
ramucirumab - Drug Profile 44
Product Description 44
Mechanism of Action 44
RandD Progress 44
RebmAb-100 - Drug Profile 48
Product Description 48
Mechanism of Action 48
RandD Progress 48
nintedanib - Drug Profile 50
Product Description 50
Mechanism of Action 50
RandD Progress 50
Carcinoembryonic Antigen-Expressing Measles Virus Vaccine - Drug Profile 52
Product Description 52
Mechanism of Action 52
RandD Progress 52
ABT-767 - Drug Profile 53
Product Description 53
Mechanism of Action 53
RandD Progress 53
²¹²Pb-TCMC-Trastuzumab - Drug Profile 54
Product Description 54
Mechanism of Action 54
RandD Progress 54
Peritoneal Tumor - Recent Pipeline Updates 56
Peritoneal Tumor - Dormant Projects 63
Peritoneal Tumor - Discontinued Products 64
Peritoneal Tumor - Product Development Milestones 65
Featured News and Press Releases 65
Nov 01, 2010: Synta Announces Gynecologic Oncology Group To Initiate Phase II Clinical Trial Of Elesclomol For Treatment Of Ovarian Cancer 65
Oct 22, 2010: M's Science Corporation Sells Its HF10 Oncology Business To Takara Bio Inc. 65
Sep 17, 2010: M's Science Corporation Initiates Exclusive Negotiations With Takara Bio Inc. To Sell Its HF10 Oncology Business 66
Sep 02, 2010: Oncolytics Biotech Announces Phase II Ovarian Cancer Study To Be Conducted By Gynecologic Oncology Group 66
Oct 16, 2009: National Patent Granted For Developmental Product HF 10 67
Appendix 68
Methodology 68
Coverage 68
Secondary Research 68
Primary Research 68
Expert Panel Validation 68
Contact Us 69
Disclaimer 69

List of Tables

Number of Products under Development for Peritoneal Tumor, H1 2014 7
Number of Products under Development for Peritoneal Tumor - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 10
Number of Products under Investigation by Universities/Institutes, H1 2014 11
Comparative Analysis by Late Stage Development, H1 2014 12
Comparative Analysis by Clinical Stage Development, H1 2014 13
Products under Development by Companies, H1 2014 14
Products under Investigation by Universities/Institutes, H1 2014 15
Peritoneal Tumor - Pipeline by Boehringer Ingelheim GmbH, H1 2014 16
Peritoneal Tumor - Pipeline by Amgen Inc., H1 2014 17
Peritoneal Tumor - Pipeline by Eli Lilly and Company, H1 2014 18
Peritoneal Tumor - Pipeline by Cell Therapeutics, Inc., H1 2014 19
Peritoneal Tumor - Pipeline by MEI Pharma, Inc., H1 2014 20
Peritoneal Tumor - Pipeline by Recepta Biopharma S.A., H1 2014 21
Peritoneal Tumor - Pipeline by AbbVie Inc., H1 2014 22
Assessment by Monotherapy Products, H1 2014 23
Number of Products by Stage and Target, H1 2014 26
Number of Products by Stage and Mechanism of Action, H1 2014 29
Number of Products by Stage and Route of Administration, H1 2014 31
Number of Products by Stage and Molecule Type, H1 2014 33
Peritoneal Tumor Therapeutics - Recent Pipeline Updates, H1 2014 56
Peritoneal Tumor - Dormant Projects, H1 2014 63
Peritoneal Tumor - Discontinued Products, H1 2014 64

List of Figures

Number of Products under Development for Peritoneal Tumor, H1 2014 7
Number of Products under Development for Peritoneal Tumor - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Comparative Analysis by Clinical Stage Development, H1 2014 13
Assessment by Monotherapy Products, H1 2014 23
Number of Products by Top 10 Target, H1 2014 24
Number of Products by Stage and Top 10 Target, H1 2014 25
Number of Products by Top 10 Mechanism of Action, H1 2014 27
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 28
Number of Products by Top 10 Route of Administration, H1 2014 30
Number of Products by Stage and Top 10 Route of Administration, H1 2014 31
Number of Products by Top 10 Molecule Type, H1 2014 32
Number of Products by Stage and Top 10 Molecule Type, H1 2014 33

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025 Summary Cardiovascular diseases (CVD), including ischemic heart disease and stroke, are the leading causes of mortality ...

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Ulcerative Colitis: KOL Insight

Ulcerative Colitis: KOL Insight

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

Are UC biosimilars a real or perceived threat to branded drugs? Ulcerative colitis (UC) treatment is on the brink. Patents are ending on various branded drugs and clearing the way for an influx of biosimilars; ...

Hepatitis C: Kol Insight

September 2016 $ 8085

Download Unlimited Documents from Trusted Public Sources

Therapy and Hormone Market in South Korea

  • December 2016
    4 pages
  • Therapy  

    Hormone  

    Cancer  

  • South Korea  

View report >

Opioid Market in the US

  • December 2016
    14 pages
  • Opioid  

  • United States  

View report >

Therapy Market in Denmark - Forecast

  • December 2016
    12 pages
  • Therapy  

  • Denmark  

View report >

Related Market Segments :

Therapy
Cancer
Chemotherapy
Monoclonal Antibody

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.